Latest development of PARP inhibitors in ovarian cancer

被引:0
|
作者
Harano, Kenichi [1 ]
机构
[1] Natl Canc Ctr Hosp East, Dept Dev Therapeut Breast Med Oncol, Kashiwa, Chiba, Japan
关键词
D O I
10.1093/annonc/mdz336.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MS3 - 5
引用
收藏
页数:1
相关论文
共 50 条
  • [31] Making the best of PARP inhibitors in ovarian cancer
    Banerjee, Susana
    Kaye, Stan B.
    Ashworth, Alan
    NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (09) : 508 - 519
  • [32] PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca"
    Boussios, Stergios
    Karathanasi, Afroditi
    Cooke, Deirdre
    Neille, Cherie
    Sadauskaite, Agne
    Moschetta, Michele
    Zakynthinakis-Kyriakou, Nikolaos
    Pavlidis, Nicholas
    DIAGNOSTICS, 2019, 9 (02)
  • [33] Therapeutic applications of PARP inhibitors in ovarian cancer
    Xie, Hongyu
    Wang, Wenjie
    Xia, Bairong
    Jin, Weilin
    Lou, Ge
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 127
  • [34] Extending the scope of PARP inhibitors in ovarian cancer
    Ledermann, Jonathan A.
    LANCET ONCOLOGY, 2019, 20 (04): : 470 - 472
  • [35] Using PARP Inhibitors in Advanced Ovarian Cancer
    O'Cearbhaill, Roisin E.
    ONCOLOGY-NEW YORK, 2018, 32 (07): : 339 - 343
  • [36] PARP inhibitors in the treatment of ovarian cancer: a review
    Washington, Christina R.
    Moore, Kathleen N.
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2021, 33 (01) : 1 - 6
  • [37] PARP inhibitors and quality of life in ovarian cancer
    Aoki, Daisuke
    Chiyoda, Tatsuyuki
    LANCET ONCOLOGY, 2018, 19 (08): : 1012 - 1014
  • [38] The Current Landscape of PARP Inhibitors in Ovarian Cancer
    Camille C. Gunderson
    Britt K. Erickson
    Megan E. Buechel
    Kathleen N. Moore
    Current Obstetrics and Gynecology Reports, 2018, 7 (1) : 20 - 27
  • [39] PARP inhibitors for targeted treatment in ovarian cancer
    Dizon, Don S.
    LANCET, 2017, 390 (10106): : 1929 - 1930
  • [40] Appropriate Selection of PARP Inhibitors in Ovarian Cancer
    Smith, Maria
    Pothuri, Bhavana
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (06) : 887 - 903